Technical Analysis for CNCE - Concert Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 6.21 5.43% 0.32
CNCE closed up 5.43 percent on Tuesday, October 15, 2019, on 1.23 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CNCE trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 5.43%
Oversold Stochastic Weakness 5.43%
Wide Bands Range Expansion 5.61%
Oversold Stochastic Weakness 5.61%
180 Bearish Setup Bearish Swing Setup 5.97%
Wide Bands Range Expansion 5.97%

Older signals for CNCE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Concert Pharmaceuticals, Inc., a biotechnology company, develops drug candidates. Its drug candidates address various therapeutic areas, including hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, schizophrenia, multiple tumors, and hyperparathyroidism, as well as provide agents for diabetic nephropathy and other forms of chronic kidney diseases. The company also develops CTP-354, a GABA(A) receptor subtype-selective modulator for the treatment of spasticity and chronic pain. Concert Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline plc and Celgene Corporation. The company was founded in 2006 and is based in Lexington, Massachusetts.
Medicine Biotechnology Medical Specialties Life Sciences Pain New Jersey Schizophrenia Chronic Kidney Disease Tumors HIV Chronic Pain Kidney Diseases Celgene Diabetic Nephropathy Bristol Myers Squibb Summit
Is CNCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.83
52 Week Low 5.36
Average Volume 223,127
200-Day Moving Average 11.6644
50-Day Moving Average 9.341
20-Day Moving Average 7.5735
10-Day Moving Average 5.906
Average True Range 0.5897
ADX 38.85
+DI 14.4306
-DI 34.0024
Chandelier Exit (Long, 3 ATRs ) 9.4259
Chandelier Exit (Short, 3 ATRs ) 7.1291
Upper Bollinger Band 12.1178
Lower Bollinger Band 3.0292
Percent B (%b) 0.35
BandWidth 120.005282
MACD Line -1.1912
MACD Signal Line -1.1634
MACD Histogram -0.0279
Fundamentals Value
Market Cap 140.89 Million
Num Shares 22.7 Million
EPS -2.22
Price-to-Earnings (P/E) Ratio -2.80
Price-to-Sales 4493.13
Price-to-Book 5.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.02
Resistance 3 (R3) 6.96 6.64 6.89
Resistance 2 (R2) 6.64 6.43 6.67 6.84
Resistance 1 (R1) 6.42 6.30 6.53 6.48 6.79
Pivot Point 6.10 6.10 6.15 6.13 6.10
Support 1 (S1) 5.88 5.89 5.99 5.94 5.63
Support 2 (S2) 5.56 5.76 5.59 5.58
Support 3 (S3) 5.34 5.56 5.54
Support 4 (S4) 5.40